On October 13, 2026, CBS News reported that the FDA received two adverse event reports in recent months describing deaths after people used products sold as retatrutide, an investigational compound Eli Lilly is still developing. Retatrutide is not FDA approved. Neither case was part of a clinical trial, and the FDA has not said whether it verified either report.
For the research community, the story is less about one compound and more about a supply chain problem that keeps getting bigger.
Key Takeaways
• Two FDA Adverse Event Reporting System (FAERS) reports, from July and September 2026, list products claiming to be retatrutide as a "suspect product" in two deaths.
• The reports are unverified. They do not prove the material caused either death, and nobody has publicly analyzed the actual vials involved.
• Eli Lilly says it has found counterfeit products with too much, too little or the wrong active ingredient, plus contaminants.
• America's Poison Centers logged 862 retatrutide exposures in the three months ending in September, up from 460 the quarter before and 249 in the first quarter of 2026.
• In both reports, the material reached people outside any research setting. Research-use-only material is not for human use, and no legitimate supplier should provide dosing guidance.
What the reports say
The first report, filed in July by a healthcare professional, describes a 41-year-old woman who went into cardiac arrest. It notes the product came "from an unreliable source."
The second, filed in September, describes a 49-year-old patient who bought vials online after a licensed nurse reportedly shared a link and recommended amounts. The patient experienced severe dehydration, malnutrition and cardiac arrest.
Both reports came out through a Freedom of Information Act request and were redacted. CBS News could not independently verify them, and the FDA said it "generally does not discuss potential or ongoing compliance matters."
What they do not prove
FAERS is a signal-detection system, not proof of cause. Anyone can submit a report, and one report rarely settles whether a product caused an outcome. Harvard Medical School's Pieter Cohen told CBS the FDA should get hold of the material itself and analyze it.
That is the core issue. Without lot numbers, chain of custody and an independent lab analysis, nobody can say what was actually in those vials.
The regulatory backdrop
Retatrutide sits in an unusual legal spot. Eli Lilly and the FDA have been in federal court since September 2024 over whether the molecule counts as a drug or a biologic. That classification will affect its exclusivity period and Medicare price negotiation timeline. Lilly plans to submit a biologics license application in the first quarter of 2027.
Retatrutide also cannot be legally compounded today. It has no USP monograph and is not on the 503A or 503B bulk substance lists. Lilly has sued med spas, at least one compounding pharmacy and other sellers of unapproved versions.
What this means for research labs
Headlines like this one are why documentation matters more than price. Before any material reaches the bench, a lab should be able to answer four questions:
1. Is there a batch-specific Certificate of Analysis? A generic COA that does not match the lot number on the vial is a red flag.
2. Was identity confirmed, not just purity? HPLC shows purity. Mass spectrometry confirms the molecule is what the label says it is.
3. Is the testing independent? Third-party results carry more weight than in-house claims.
4. Does the supplier stay in its lane? A legitimate research supplier never gives human-use or dosing advice, and never markets research material to patients.
If a supplier cannot answer all four, the material should not be used.
Our position
Kynetide supplies research compounds for laboratory use only. We publish batch-specific, third-party COAs and do not provide dosing, injection or human-use guidance of any kind. We also believe that healthcare professionals recommending research-use-only material to patients is a serious problem for the whole research community.
Sources: CBS News, "Two deaths were reported to the FDA. Is the bootleg weight-loss drug 'Reta' to blame?" (October 2026); AJMC, "5 Things to Know if Retatrutide Is Classified as a Biologic" (October 7, 2026).
FDA Disclaimer: The statements and products on this site have not been evaluated by the Food and Drug Administration. All Kynetide products are sold strictly for laboratory research use only. They are not intended to diagnose, treat, cure or prevent any disease, and are not for human or animal consumption.
